Carotid Artery and Cerebral Atherosclerosis, Transient Ischemic Attacks, Symptoms and Signs Correlated with Lesions at Various Brain Locations, Cervical and Cranial Arterial Dissections, and Hydrocephalus and Gait Abnormalities

2020 ◽  
pp. 192-212
Author(s):  
Louis R. Caplan
Keyword(s):  
Internal Medicine ◽  
Older Adults ◽  
Carotid Artery ◽  
Cerebrovascular Disease ◽  
Brain Ischemia ◽  
Transient Ischemic Attacks ◽  
Cerebral Atherosclerosis ◽  
Gait Abnormalities ◽  
Symptoms And Signs

Abstract: This chapter describes Fisher’s contributions in regard to the presence, nature, and severity of carotid artery and cerebral atherosclerosis and the symptoms and signs in patients with brain ischemia and infarction; transient ischemic attacks; the nature and symptoms related to dissection of brain-supplying arteries; and hydrocephalus and gait abnormalities in older adults. Fisher made many contributions to medicine. Arguably his major contribution to the care of patients with cerebrovascular disease and brain ischemia and strokes was his lengthy descriptions and diagrams of the symptoms and signs in patients with occlusive cerebrovascular disease that appeared in textbooks of internal medicine and neurology.

Increase in plasma adenosine during brain ischemia in man: A study during transient ischemic attacks, and stroke

2000 ◽  
Vol 51 (4) ◽  
pp. 327-330 ◽  
Author(s):  
Franco Laghi Pasini ◽  
Francesca Guideri ◽  
Eugenio Picano ◽  
Giuliano Parenti ◽  
Christina Petersen ◽  
...  
Keyword(s):  
Brain Ischemia ◽  
Transient Ischemic Attacks ◽  
Plasma Adenosine

scholarly journals Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Victoria S. Marshe ◽  
Malgorzata Maciukiewicz ◽  
Anne-Christin Hauschild ◽  
Farhana Islam ◽  
Li Qin ◽  
...  
Keyword(s):  
Older Adults ◽  
Cerebrovascular Disease ◽  
Protein Degradation ◽  
Late Life ◽  
Cardioembolic Stroke ◽  
Symptom Improvement ◽  
Antidepressant Response ◽  
Polygenic Risk ◽  
Remission Status ◽  
Genome Wide

AbstractAntidepressant outcomes in older adults with depression is poor, possibly because of comorbidities such as cerebrovascular disease. Therefore, we leveraged multiple genome-wide approaches to understand the genetic architecture of antidepressant response. Our sample included 307 older adults (≥60 years) with current major depression, treated with venlafaxine extended-release for 12 weeks. A standard genome-wide association study (GWAS) was conducted for post-treatment remission status, followed by in silico biological characterization of associated genes, as well as polygenic risk scoring for depression, neurodegenerative and cerebrovascular disease. The top-associated variants for remission status and percentage symptom improvement were PIEZO1 rs12597726 (OR = 0.33 [0.21, 0.51], p = 1.42 × 10−6) and intergenic rs6916777 (Beta = 14.03 [8.47, 19.59], p = 1.25 × 10−6), respectively. Pathway analysis revealed significant contributions from genes involved in the ubiquitin-proteasome system, which regulates intracellular protein degradation with has implications for inflammation, as well as atherosclerotic cardiovascular disease (n = 25 of 190 genes, p = 8.03 × 10−6, FDR-corrected p = 0.01). Given the polygenicity of complex outcomes such as antidepressant response, we also explored 11 polygenic risk scores associated with risk for Alzheimer’s disease and stroke. Of the 11 scores, risk for cardioembolic stroke was the second-best predictor of non-remission, after being male (Accuracy = 0.70 [0.59, 0.79], Sensitivity = 0.72, Specificity = 0.67; p = 2.45 × 10−4). Although our findings did not reach genome-wide significance, they point to previously-implicated mechanisms and provide support for the roles of vascular and inflammatory pathways in LLD. Overall, significant enrichment of genes involved in protein degradation pathways that may be impaired, as well as the predictive capacity of risk for cardioembolic stroke, support a link between late-life depression remission and risk for vascular dysfunction.

Direct percutaneous cerebral angiography in neurosurgical practice

1980 ◽  
Vol 52 (4) ◽  
pp. 525-528 ◽  
Author(s):  
Jerry Bauer ◽  
Jose Luis Salazar ◽  
Oscar Sugar ◽  
Ronald P. Pawl
Keyword(s):  
High Risk ◽  
Cerebrovascular Disease ◽  
Cerebral Angiography ◽  
Complication Rate ◽  
High Risk Population ◽  
Content Type ◽  
Pros And Cons ◽  
Sixth Decade ◽  
Symptoms And Signs ◽  
Fine Print

✓ A retrospective analysis of 1171 consecutive percutaneous retrograde brachial and carotid cerebral angiograms was performed on 635 patients, 50.7% of whom were in the sixth decade or older. Symptoms and signs of cerebrovascular disease were the most frequently investigated and diagnosed, accounting for 46.7% of all the angiograms. Despite this relatively high-risk population, we have found direct percutaneous cerebral angiography to have a very low risk. The pros and cons of direct percutaneous versus transfemoral cerebral angiography are discussed. The literature of the previous 10 years is reviewed, and the complication rate of these two techniques is compared.

scholarly journals Extraintracranial Bypass as a Rescue Therapy for Symptomatic Flow Diverter Thrombosis

2015 ◽  
Vol 2015 ◽  
pp. 1-5
Author(s):  
Luigi A. Lanterna ◽  
Alessandro Lunghi ◽  
Carlo Brembilla ◽  
Paolo Gritti ◽  
Claudio Bernucci
Keyword(s):  
Carotid Artery ◽  
Internal Carotid Artery ◽  
Internal Carotid ◽  
Rescue Therapy ◽  
Flow Diverter ◽  
Minor Stroke ◽  
Transient Ischemic Attacks ◽  
Postoperative Course ◽  
A Minor ◽  
Ischemic Events

A 56-year-old female with a giant partially thrombosed unruptured carotid-ophthalmic aneurysm was treated with a Pipeline flow diverter. Three months after the procedure, in concomitance with the discontinuation of one of the antiplatelet medications, the patient suffered from a minor stroke and relapsing transient ischemic attacks. The angiography demonstrated the occlusion of the internal carotid artery, and a perfusion-weighted CT scan showed a condition of hypoperfusion. The patient underwent a double-barrel extraintracranial bypass. The postoperative course was uneventful and she has experienced no further ischemic events to date.

scholarly journals APOE genotypes as a risk factor for age-dependent accumulation of cerebrovascular disease in older adults

2018 ◽  
Vol 15 (2) ◽  
pp. 258-266 ◽  
Author(s):  
Melissa Lamar ◽  
Lei Yu ◽  
Leah H. Rubin ◽  
Bryan D. James ◽  
Lisa L. Barnes ◽  
...  
Keyword(s):  
Older Adults ◽  
Risk Factor ◽  
Cerebrovascular Disease ◽  
Age Dependent ◽  
Apoe Genotypes

scholarly journals Internal carotid artery blood flow response to cognitive task is similar between young and older adults

2020 ◽  
Vol 34 (S1) ◽  
pp. 1-1
Author(s):  
Ryota Asahara ◽  
Kei Ishii ◽  
Tsubasa Izaki ◽  
Sunao Iwaki ◽  
Hidehiko Komine
Keyword(s):  
Older Adults ◽  
Blood Flow ◽  
Carotid Artery ◽  
Internal Carotid Artery ◽  
Internal Carotid ◽  
Cognitive Task ◽  
Artery Blood Flow ◽  
Blood Flow Response ◽  
Flow Response

scholarly journals Experience of the use of the PCSK9 inhibitor Alirocumab in patients with extremely high cardiovascular risk

Kardiologiia ◽  
2020 ◽  
Vol 60 (8) ◽  
pp. 71-77
Author(s):  
V. A. Korneva ◽  
T. Yu. Kuznetsova ◽  
I. S. Scopetc ◽  
N. N. Vezikova
Keyword(s):  
Acute Coronary Syndrome ◽  
Cardiovascular Risk ◽  
Cerebrovascular Disease ◽  
Laboratory Data ◽  
Myocardial Revascularization ◽  
Real Life ◽  
Transient Ischemic Attacks ◽  
High Cardiovascular Risk ◽  
Pcsk9 Inhibitor ◽  
Coronary Syndrome

Aim To study the efficacy and safety of alirocumab in patients with high and very high cardiovascular risk in the Republic of Karelia and to evaluate their compliance with the alirocumab therapy.Materials and methods Study design: observational, noncomparative. The observation group consisted of 9 patients receiving alirocumab (Praluent®) (mean age, 48.6±4.7 years; 7 men). 7 patients had familial hypercholesterolemia of the type diagnosed by DLCN criteria; five patients had MI. Lipid profile, concentrations of transaminases, creatinine, glucose, and lipoprotein a (LP(a)) were measured at 3, 6, 12, and 18 months. Electrocardiography was performed, and the clinical picture (development of acute coronary syndrome, acute cerebrovascular disease, transient ischemic attacks, myocardial revascularization, and cardiovascular death) was evaluated. Efficacy criteria included the absence of these clinical conditions, the proportion of patients who achieved the LDL CS goal, and the decrease in LP(a). Safety was evaluated by clinical and laboratory data, such as levels of transaminases, total bilirubin, creatinine, and blood glucose. The observation lasted for 6 months to 1.5 years.Results LDL CS goals were achieved in 7 (77.8%) patients receiving alirocumab. The mean level of LP(a) decreased from 0.39 to 0.28 g/l; the degree of decrease ranged from 20 to 33 %. No cases of IHD instability (acute coronary syndrome) or new cases of acute cerebrovascular disease and transient ischemic attacks were observed. None of the patients had to stop the alirocumab treatment; adverse effects, including local ones, were not observed.Conclusion LDL CS goals were achieved in 7 (77.8%) patients. The level of LP(a) decreased by 20-33% in patients receiving the PCSK9 inhibitor. In real-life clinical practice, the alirocumab treatment was characterized with high compliance and good tolerability without side effects, including local ones.

Sign in / Sign up

Export Citation Format

Share Document